key: cord-0732621-qozhbi62
authors: Wagner, Karolin I.; Mateyka, Laura M.; Jarosch, Sebastian; Grass, Vincent; Weber, Simone; Schober, Kilian; Hammel, Monika; Burrell, Teresa; Kalali, Behnam; Poppert, Holger; Beyer, Henriette; Schambeck, Sophia; Holdenrieder, Stefan; Strötges-Achatz, Andrea; Haselmann, Verena; Neumaier, Michael; Erber, Johanna; Priller, Alina; Yazici, Sarah; Roggendorf, Hedwig; Odendahl, Marcus; Tonn, Torsten; Dick, Andrea; Witter, Klaus; Mijočević, Hrvoje; Protzer, Ulrike; Knolle, Percy A.; Pichlmair, Andreas; Crowell, Claudia S.; Gerhard, Markus; D’Ippolito, Elvira; Busch, Dirk H.
title: Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection
date: 2021-12-17
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.110214
sha: 42099f7bef5deb255b08df36f0cc70c89154b86f
doc_id: 732621
cord_uid: qozhbi62

T cell immunity is crucial for the control of SARS-CoV-2 infections and has been widely studied on a quantitative level. However, quality of responses, in particular of CD8+ T cells, has only been marginally investigated so far. Here, we isolate T cell receptor (TCR) repertoires specific for immunodominant SARS-CoV-2 epitopes restricted to common Human Leucocyte Antigen (HLA) class I molecules in convalescent individuals. SARS-CoV-2-specific CD8+ T cells are detected up to twelve months from infection. TCR repertoires are diverse, with heterogeneous functional avidity and cytotoxicity towards virus-infected cells, as demonstrated for TCR-engineered T cells. High TCR functionality correlates with gene signatures that, remarkably, could be retrieved for each epitope:HLA combination analyzed. Overall, our data demonstrate that polyclonal and highly functional CD8+ TCRs – classical features of protective immunity - are recruited upon mild SARS-CoV-2 infection, providing tools to assess the quality and to potentially restore functional CD8+ T cell immunity.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus responsible for the Coronavirus Disease 2019 , a pathological condition that can progress to severe pneumonia and a fatal outcome (Zhou et al., 2020; Zhu et al., 2020) . The adaptive immune system plays a critical role in SARS-CoV-2 infections. In most cases, T and B cells react quickly and in a coordinated manner to the infection (Mathew et al., 2020; Rydyznski Moderbacher et al., 2020; Suthar et al., 2020) and develop a robust memory pool detectable months after exposure regardless of disease severity (Peng et al., 2020; Sekine et al., 2020; Sokal et al., 2021) . In line with that, individuals who recovered from COVID-19 experienced low reinfection rates, in particular for symptomatic infections (Deng et al., 2020; Hall et al., 2021; Hansen et al., 2021) . In contrast, severe clinical manifestations occurred in the less frequent scenario where immune responses were suboptimali.e. in elderly individuals where antigen presentation is less efficient and the pool of naïve T cells is scarce (Bacher et al., 2020; Rydyznski Moderbacher et al., 2020) . Despite the increasing understanding of SARS-CoV-2 immunity, a clear correlate of protection is still missing. This is of paramount importance as it would allow for the identification of individuals with minimal risk of reinfection as well as the minority of patients with high risk of developing severe symptoms due to lack of adequate immunity. In addition, it would provide relevant platforms or tools for the validation of candidate vaccines, including immunity towards virus variants.

Antibody titers have been extensively used to describe SARS-CoV-2 adaptive immunity as their detection is suitable for high-throughput testing and intrinsically mirrors an adequate recruitment of CD4 + T cells. However, the role of antibodies in protective immunity is still controversial. Seropositive convalescent individuals showed lower risk of reinfections (Addetia et al., 2020; Hall et al., 2021; Lumley et al., 2021) but neither total nor neutralizing antibody titers protected from severe symptoms during primary infections (Rydyznski Tan et al., 2021) . In addition, the resolution of SARS-CoV-2 infections in individuals SARS-CoV-2-specific T cell immunity has been widely characterized quantitatively (Bacher et al., 2020; Peng et al., 2020; Quadeer et al., 2021; Sekine et al., 2020; Tarke et al., 2021) .

However, little is known about their quality, and thereby determinants of protection. This lack of knowledge in the COVID-19 field mainly derives from the broad use of single dose peptide mixes (15-mers) for T cell analyses, which are often preferred as they can be designed easily

to cover entire open reading frames (ORFs). Their usage was highly valuable to gain information on the magnitude and breadth of SARS-CoV-2 T cell responses in a remarkably short time (Peng et al., 2020; Tarke et al., 2021) but at the expense of precision, i.e. specificity and quality of single-epitope responses. Indeed, the epitopes responsible for the observed T cell reactivity are often unknown and peptide mixes are usually used at a single high concentration, which hinders discrimination of high (protective) and low (suboptimal) functional T cells. This information has become extremely relevant as i) high frequency of cross-reactivity with common cold coronaviruses was reported, even though mainly for CD4 + T cells (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020; Mateus et al., 2020; Schulien et al., 2020) , and ii) suboptimal -but high-frequency -T cell responses were observed in severe COVID-19 patients due to recruitment of low functional cross-reactive memory T cells rather than highly specific naïve T cells (Bacher et al., 2020) . Finally, CD8 + T cell responses are still underrepresented, and thereby less investigated, as 15-mer peptides primarily stimulate CD4 + T cells . Altogether, this evidence underlines how the detection and magnitude of T cell responses is not always equivalent to functionality.

Thus, we decided to investigate in depth the quality of SARS-CoV-2-specific CD8 + T cells through the analyses of their T cell receptor (TCR) repertoire. A TCR is the fingerprint of a T cell and determines its specificity, functionality and fate. Furthermore, preclinical studies have shown that highly functional TCRs drive the establishment of protective immunity in infectious diseases, as they dominate primary infections (Zehn et al., 2009) and react faster to recall infections (Busch and Pamer, 1999) . By analyzing the SARS-CoV-2 epitope-specific TCR repertoire in convalescent individuals who experienced mild symptoms and for whom, thereby, a protective immunity should have established, we could show that highly functional and polyclonal TCRs are recruited in CD8 + T cell responses against SARS-CoV-2 during nonsevere disease.

To study SARS-CoV-2-specific CD8 + T cell responses, we designed a pool of SARS-CoV-2 peptides (9-mer) predicted to be immunogenic for the most common HLA class I molecules (HLA-A*01:01, A*02:01, A*03:01, A*11:01, A*24:02, B*07:02, B*08:01, B*35:01). This HLA combination covers 73% of the European Caucasian population, 78% of Australia, 76% of J o u r n a l P r e -p r o o f Central and South America, 69% of North America, 75% of Northeast Asia but only 53% of North Africa, 61% of South Asia and 54% of Western Asia (cumulative HLA allele frequency, allelefrequencies.net, similar to (Effenberger et al., 2019) ). We finally selected 40 candidates, among which nine showed 100% homology with SARS-CoV (Table S1 ). No homology was found with published epitopes (IEBD databank) from "common cold" coronaviruses (CCCoVs: 229E, NL63, HKU1, OC43, degree of homology higher than 70%) and no hits with less than four amino acid exchange were found in the global CCCoVs genome (Table S2) . Considering the strict rules that govern the epitope binding to HLA class I molecules, this degree of homology strongly speaks against possible cross-reactivity between SARS-CoV-2 and CCCoVs epitopes.

SARS-CoV-2 T cell responses contract and become barely detectable ex vivo within a few weeks after infection . Our cohort of convalescent individuals (PCR+ with mild course of disease and no need of hospitalization, referred to as mild COVID-19 from now on) comprised of blood sampled at least 30-50 days after infection. Therefore, we tested the sensitivity of ex vivo responses to a commercially available peptide mix of the Spike (S) protein (Peptivator S, 15-mer mix) and, as expected, we detected low frequency but reliable T cell responses in most mild COVID-19, despite mainly in CD8 -T cells ( Figure S1A -B). Stimulation with our 9-mer pool, however, indicated detectable T cell responses in only few individuals.

Size of frequencies and robustness of detection were in addition suboptimal ( Figure S1A -B), primarily due to the small size of our pool (4-fold lower number of peptides than Peptivator S pool). Thus, in order to detect such low frequency SARS-CoV-2-reactive CD8 + T cell populations, we adapted an expansion protocol where T cells are stimulated with autologous pulsed PBMCs and in vitro expanded prior re-challenge and T cell functional analyses (Oh et al., 2011) (Figure 1A) . We successfully observed SARS-CoV-2 T cell responses after expansion within a set of mild COVID-19 subjects; furthermore, as expected by the design of the 9-mer peptide pool, primarily CD8 + but not CD8 -T cells responded to the stimulation ( Figure   S1C -D).

We next studied such T cell responses across four distinct cohorts: 53 mild COVID-19; 28 asymptomatic seropositive individuals; 37 asymptomatic individuals who continuously tested seronegative for SARS-CoV-2 IgG antibodies throughout the observation period; 28 unexposed individuals for whom blood was collected before the outbreak (Table S3) .

Mild COVID-19 and asymptomatic seropositive individuals showed strong, although variable, CD8 + T cell response rates (81% and 78%, respectively). In contrast, responses were observed in a small proportion of asymptomatic seronegative and unexposed individuals, the J o u r n a l P r e -p r o o f latter also particularly weak (Figure 1 B-C). T cell responses can develop in absence of antibody production (Sekine et al., 2020) , supporting our findings in the asymptomatic seronegative individuals. Reactivity in pre-pandemic individuals, instead, has been explained as cross-reactive T cells Nelde et al., 2020; Schulien et al., 2020) or associated to an exceptionally high naïve precursor frequency (Nguyen et al., 2021) . As before, CD8 + T cells dominated the overall T cell responses after in vitro peptide expansion ( Figure   1C and Figure S1E ). Importantly, for the majority of HLA class I molecules included in the SARS-CoV-2 epitope prediction, the coverage among the four cohorts was at comparable levels ( Figure S2 ), thus excluding a bias in T cell responses due to a different HLA representation.

Except for pre-pandemic donors, blood was collected over several months, thus allowing us to investigate the longevity of SARS-CoV-2 CD8 + T cell immunity. We first looked at CD8 + T cell responses and antibody titers at early time points after diagnosis (PCR test) for mild COVID-19 and after enrollment in the study for asymptomatic seropositive cohorts. We observed concomitantly detectable levels of SARS-CoV-2-specific IgG and CD8 + T cells in the majority of individuals ( Figure 1D ). This is in line with previous reports describing coordinated responses of the humoral and T cell arms in individuals who resolved the infection without severe symptoms (Rydyznski . Despite the fact that antibody titers rapidly waning over time ( Figure 1E ), SARS-CoV-2-specific CD8 + T cells remained relatively stable ( Figure 1F ), similar to other reports (Peng et al., 2020; Sherina et al., 2021a) and, remarkably, were detected up to twelve months post-infection ( Figure 1G ).

Overall, we could show that the designed 9-mer pool can be used to detect SARS-CoV-2 CD8 + T cell responses regardless of symptom severity, and that long-lasting CD8 + T cell immunity establishes upon primary infection.

Before investigating the functionality of SARS-CoV-2-specific TCR repertoires, we searched our 9-mer pool for immunodominant epitopes, in order to study CD8 + T cell responses specific for single epitopes that might have high relevance in SARS-CoV-2 infections.

To do so, we applied a two-step deconvolution process, where expanded PBMCs were first re-stimulated with one of four distinct sub-pools, each composed of 8-12 peptides, and then analyzed for the individual epitopes of the reactive sub-pools. We performed this deconvolution on mild COVID-19 responders for whom HLA class I genotyping was available. In total, we found 19 immunogenic peptides, despite a certain variability in the magnitude of responses and the number of responders (Figure 2A and S3). Except for ORF1_LTN and ORF1_HSI, immunogenicity of the remaining epitopes was reported also in other studies (Le Bert et al., 2020; Ferretti et al., 2020; Habel et al., 2020; Nelde et al., 2020; Peng et al., 2020; Schulien et J o u r n a l P r e -p r o o f al., 2020) (Table S1 ). Interestingly, we often observed CD8 + T cell responses against multiple epitopes deriving from the same SARS-CoV-2 ORF (e.g. donor #11 and #12) as well as from different ORFs in individual donors (e.g. donor #14 and #24) (Figure 2A ), indicating that broad and polyclonal CD8 + T cell response are elicited upon infection.

We also assessed the specificity of the identified immunogenic epitopes to SARS-CoV-2 through evaluation of single-peptide responses in pre-pandemic responders. Only in four of them we confirmed CD8 + T cell reactivity. In addition, we observed responses to only one epitope per donor and at low magnitude (Figure 2A ), overall highlighting how less consistent these responses are compared to mild COVID-19. All four epitopes stimulating CD8 + T cells in pre-pandemic individuals were found immunogenic also in mild COVID-19. Despite similar frequencies in unexposed individuals (except for B35/ORF1_VPF), ORF1_DTD and ORF3_FTS epitopes showed remarkably high immunodominance in mild COVID-19 ( Figure   2B ), which could be explained by an unusually high naïve precursor frequency (Nguyen et al., 2021) or pre-existing immunity (Niessl et al., 2021) . In contrast, similar percentages of responders were found in mild COVID-19 and unexposed individuals for A2/N_LLL and B35/OFR1_VPF epitopes, which would more support the hypothesis of cross-reactive epitopes with limited relevance in SARS-CoV-2 infections. Additional analyses would be necessary to comprehensively decipher the source of pre-pandemic responses.

Next, to understand the relevance of the identified immunogenic epitopes in SARS-CoV-2 T cell immunity, we quantified their immunodominance. Among the 19 immunogenic SARS-CoV-2 epitopes, eleven showed immunodominance of at least 50% ( Figure 2C ). By combining the responses of individual epitopes restricted to the same HLA class I molecule, we achieved a response rate of 100% for HLA-A*01:01, HLA-A*11:01 and B*35:02, 63% for HLA-A*03:01 but only 40% for HLA-A*02:01, 33% for HLA-B*08:01 and less than 15% or no responses for the remaining HLAs ( Figure S4A ). To increase HLA coverage, we further tested a second pool of SARS-CoV-2-derived 9-mers composed of a mixture of newly predicted and published epitopes (Table S1 ). We confirmed additional 27 immunogenic epitopes, of which 17 displayed an immunodominance higher than 50% ( Figure 2D and S4B); furthermore, we sharply increased the response rate for HLA-A*02:01 (70%), A*24:02 (78%), B*07:02 (100%) and gained coverage for HLA-B*40:01 (100%) and B*44:03 (60%) ( Figure S4A ).

Overall, we identified a pool of immunodominant SARS-CoV-2 epitopes that could specifically identify individuals who had been exposed to the virus. Indeed, despite sporadic responses in non-infected individuals, the pattern of multiple-epitope responses makes convalescent COVID-19 individuals uniquely distinguishable.

J o u r n a l P r e -p r o o f Previous analyses have revealed several promising CD8 + T cell epitopes with high immunodominance and specificity to SARS-CoV-2, but without providing any information on the quality of the detected T cell responses. To fill this knowledge gap, we identified and functionally characterized SARS-CoV-2 epitope-specific TCR repertoires.

We first focused on two immunodominant SARS-CoV-2 epitopes restricted to frequent HLA class I molecules (A1/ORF3a_FTS and A3/ORF1_VTN). PBMCs from HLA-matched, mild COVID-19 individuals were expanded on the 9-mer pool and re-challenged with individual epitopes prior to flow-cytometric cell sorting followed by single-cell RNA sequencing (scRNAseq). In addition to CD8 + IFN-γ + T cells, which should be enriched in freshly re-activated T cells specific for the investigated epitopes, we also sorted CD8 + IFN-γ -T cells where TCRs specific for other immunogenic epitopes of the 9-mer pool or completely unrelated pathogens could be found ( Figure 3A and S5A). Moreover, sorting of IFN-γ-secreting cells ensured to quantitatively catch most of the TCR repertoire, otherwise potentially limited by the relative low frequency of IFN-γ + CD8 + T cells; IFN-γsorted T cells, instead, also served as control group for comparative transcriptomic analyses. In this way, on the one hand, most of the information about SARS-CoV-2-specific TCR repertoire of a donor would be retrieved without losing focus on the epitopes of highest interest. On the other hand, the potential of gene signatures to infer TCR specificity and functionality may be explored.

Analysis of clonotypic expansion and Leiden clustering revealed that the most expanded TCR clonotypes were present in clusters 0, 1 and 5 ( Figure 3B -C), indicating that these three clusters may contain activated and expanded SARS-CoV-2-specific T cells. Particularly cluster 1 contained cells with high, and for some markers unique, expression of effector molecules (IFNG, GZMB and IL-2) and activation markers (XCL1, CD69 and CRTAM) ( Figure 3D ). The XCL1 chemokine is produced by activated T cells during infections and inflammatory responses and interacts with the XCR1 receptor on dendritic cells, thereby promoting dendritic cell-mediated cytotoxic immune responses (Brewitz et al., 2017) . CRTAM is expressed on activated T cells (Patiño-Lopez et al., 2006; Rojas-Marquez et al., 2015) and coordinates cell polarity during activation, which was shown crucial for production of effector cytokines (Yeh et al., 2008) . Together with the up-regulation of IFNG, GZMB, IL-2 and CD69 genes, this signature of recent activation may suggest an enrichment of T cells specific for A1/ORF3a_FTS and A3/ORF1_VTN epitopes in cluster 1. Considering the basal levels of GzmB in memory T cells (Grossman et al., 2004; Lin et al., 2014) , the only expression of GZMB but not IFNG, XCL1 and IL-2 in clusters 0 and 5 suggested, instead, the presence of late activated T cells, presumably reactive towards SARS-CoV-2 epitopes other than A1/ORF3a_FTS and A3/ORF1_VTN. Pooled samples were deconvoluted according to single nucleotide polymorphisms (Xu et al., 2019) and assigned to an individual donor by sex and HLA class I genotype ( Figure S5B -E).

All donors showed a polyclonal TCR repertoire ( Figure 3E ) with the dominating clonotypes distributed among clusters 0, 1 and 5 ( Figure 3F ). The TCR repertoire for cluster 1 (IFNG + cluster) was highly diverse, in particular in case of ORF3a_FTS, and showed a higher fraction of clonally expanded TCRs ( Figure 3E ).

In summary, we found that SARS-CoV-2-specific TCR repertoires are highly polyclonal with some clonotypes showing a prominent signature of recent activation, presumably reflecting fresh re-stimulation.

To investigate the quality of the identified SARS-CoV-2-specific TCR repertoires, we next reexpressed candidate TCRs for functional characterization by CRISPR/Cas9-mediated orthotopic TCR replacement (OTR). Hereby, complete replacement of the endogenous TCR is achieved by transgenic TCR knockin into the endogenous TCR α locus and concomitant TCR β locus knockout . We selected TCRs from both cluster 1 and clusters 0 and 5 among the top 10 expanded clonotypes ( Figure 3F , S5E-F and Table S4 ).

Thus, potential associations between TCR specificity/functionality and the observed activation signature could be analyzed.

We first validated the specificity of our transgenic TCRs via epitope-HLA multimer staining, as false epitope-specific TCRs may be retrieved. All TCRs selected from cluster 1 (IFNG + cluster) showed strong staining toward relevant multimers (ORF1_VTN and ORF3a_FTS), except for A3/TCR 32 that stained weaker; no reactivity was observed against irrelevant multimers (HLA-A*03:01 or HLA-A*01:01 multimers loaded with a different epitope), thus confirming specific epitope recognition ( Figure 4A -B). Instead, none of the TCRs selected from clusters 0 and 5 (IFNGcluster) reacted to the relevant multimers, but A3/TCR 40 showed specificity for ORF1_KLF ( Figure 4A -B). To decipher the specificity of the remaining IFNGclusters-derived TCRs, we stimulated TCR-engineered T cells with autologous PBMCs pulsed with SARS-CoV-2 9-mer, CMV and EBV peptide pools, due to the high prevalence of CMV and EVB infections in the human population and the induced big-size T cell responses (Callan et al., 1996; Sylwester et al., 2005) . Cytokine release was observed only for A1/TCR 3399. ( Figure S6 ).

Altogether, HLA multimer staining confirmed that cluster 1 was enriched in freshly restimulated TCRs, and that signatures of recent activation are indicative of TCR specificity to recent epitope re-challenge.

TCRs with clear specificity for SARS-CoV-2 epitopes were further characterized. All TCRengineered T cells responded to the cognate peptide stimulus in a dose-dependent manner, and the majority showed sensitivity to very low peptide concentrations, as indicated by the IFNγ EC50 values. A3/TCR 13, A3/TCR 28, A1/TCR 3398 and A1/TCR 3456 showed particularly high functionality with half-maximum cytokine release at peptide stimulation above 10 -7 M, To test for cytotoxicity, we generated a target cell line susceptible to SARS-CoV-2 infection.

Briefly, the A549 human lung cancer cell line was engineered to express the ACE2 protein, red fluorescent protein and HLA-A*01:01 or HLA-A*03:01 molecules, which allowed viral infection, live-cell imaging acquisition and appropriate epitope presentation, respectively. A genetically modified GFP-expressing SARS-CoV-2 virus was used for infection. After viral infection, addition of TCR-engineered T cells successfully blocked viral spread (GFP signal) and induced killing of infected target cells (RPF + GFP + ) with minimal off-target toxicity on noninfected cells (RFP + ) ( Figure 4E -F). Only A3/TCR 32 showed again extremely low functionality, in line with the low levels of cytokine release upon epitope re-stimulation.

In summary, we showed that the TCR repertoire specific for SARS-CoV-2 ORF1_VTN and ORF3a_FTS epitopes contains highly functional and cytotoxic TCRs. Furthermore, expression of genes related to recent activation is indicative of epitope specificity.

The validated TCRs compose only a minor part of the total repertoire we isolated from ORF1_VTN and ORF3a_FTS specific T cells. Expression of IFNG, among other genes, was indicative of epitope specificity, as it reflected reactivity after fresh re-stimulation prior to sorting and sequencing. Therefore, we searched our transcriptomic dataset for gene signatures that could associate with T cell functionality in order to accurately predict functionality also for nonvalidated TCRs.

Taking into consideration that TCRs were isolated from in vitro expanded CD8 + T cells after fresh re-stimulation, we analyzed the predictive potential of an available gene signature related to CD8 + T cell activation. The CD8 + T cell activation score was enriched in cells expressing freshly re-stimulated TCRs, but it showed only a trend of correlation with T cell functionality among the reactive TCRs (IFN-γ EC50) ( Figure 5A ). To improve the sensitivity of prediction, we defined two additional gene signatures more specific for our dataset and based on gene expression of cells expressing the TCRs that we selected for re-expression and characterization; a "reactivity signature" composed of genes differentially expressed between epitope-reactive TCRs and non-reactive TCRs ( Figure S7A ), and a "functionality signature" comprising genes that best correlated with IFN-γ EC50 ( Figure S7B -C). Epitope-reactive TCRs showed high scores for both signatures and, remarkably, the functionality score accurately predicted T cell functionality. The percentage of IFNG + cells, but not the clonotype size, also clearly identified epitope-reactive TCRs but was not sufficient to resolve low (TCR 32) and highly functional TCRs (TCR 13 and TCR 28 among others) ( Figure 5A ). When applied to the J o u r n a l P r e -p r o o f entire identified TCR repertoires, high activation and functionality scores clearly separated and identified SARS-CoV-2-specific T cells responding to the recent re-stimulation, which were almost all belonging to the IFNG + cluster ( Figure 5B ). More importantly, within the reactive TCRs, clonotypes distributed among a range of signature scores. We found a relevant proportion of TCRs with scores similar to the high-avidity TCRs (3456, 3398, 28 and 13), except for Donor 22 for whom higher amount of low functional TCRs was observed.

Intriguingly, low-avidity TCR 32 correspondingly showed an intermediate positioning in the activation/proliferation score landscape ( Figure 5B ). Overall, our data indicate that a polyclonal population of highly functional TCRs is recruited in mild COVID-19, despite a variable proportion of intermediate and low avidity TCRs.

We finally expanded this TCR repertoire analysis to nine additional immunodominant SARS-CoV-2 epitopes restricted to five different HLA class I molecules in eight mild COVID-19 individuals. Each donor was stimulated with specific epitopes of interest and expanded in vitro prior to re-stimulation and sorting of CD8 + IFN-γ + cells. Each sample was additionally labeled with a DNA-tagged antibody in order to make it distinguishable when pooled with other donors for scRNA-seq ( Figure 6A ). Despite sorting, transcriptomic data revealed heterogeneous expression of genes related to T cell function and activation, which resulted in different enrichments in the reactivity, functionality and activation scores ( Figure 6B ). High reactivity scores were broadly observed, suggesting that the majority of the isolated repertoires should be specific to SARS-CoV-2. In addition, a fraction of those TCRs was particularly enriched also in the functionality score, as well as in the activation score, indicating the presence of TCRs of presumably high functionality ( Figure 6B ). For a better evaluation, we correlated the reactivity and functionality scores for each clonotype of the newly identified repertoires, and we used the in vitro characterized TCRs as controls. We observed a bimodal distribution, with the functional transgenic TCRs (13, 28, 43, 3456 and 3398) occupying the score high cluster and the lowavidity (TCR 32)/non-specific TCRs (18, 40, 82, 3409 and 3399) showing low scores. All other clonotypes distributed within the reactivity/functionality landscape and a relevant number of clonotypes overlaid with highly functional transgenic TCRs ( Figure 6C ), thus further corroborating our initial observations. As a final step, we wanted to understand the functional landscape of epitope-specific TCR repertoires. After deconvolution, most of the donors showed again a highly polyclonal TCR repertoire ( Figure 6D ). Remarkably, highly functional TCRs (defined by high gene signature scores) were predicted for all donors and analyzed SARS-CoV-2 epitopes ( Figure 6E ).

Overall, we could show that polyclonal CD8 + T cell responses are elicited against immunodominant SARS-CoV-2 epitopes and that highly functional TCRs are recruited in mild COVID-19, despite some variability according to HLA-epitope combination.

J o u r n a l P r e -p r o o f

The importance of CD8 + T cells in respiratory virus infections is well recognized. CD8 + T cells are recruited to the lungs within 8-10 days from infection (Flynn et al., 1998; Heidema et al., 2008; Lukens et al., 2006) , contribute to viral clearance (Jozwik et al., 2015; Lukacher et al., 1984; Yap et al., 1978) , and generate a pool of memory cells that protect from re-infection (Heidema et al., 2008; Jozwik et al., 2015) . Also in SARS-CoV infections, CD8 + T cells provided substantial protection in preclinical studies (Channappanavar et al., 2014) and long-lasting memory SARS-CoV-specific CD8 + T cells have been detected up to 17 years after infection in humans (Le Bert et al., 2020) . T cell immunity against SARS-CoV-2 shares many of the abovementioned aspects. Early recruitment of T cells prevented severe disease (Tan et al., 2021) and was usually followed by the establishment of a robust pool of functional memory T cells (Schulien et al., 2020; Sekine et al., 2020) detectable up to 6-10 months after infection (Dan et al., 2021; Jung et al., 2021; Sherina et al., 2021b; Zuo et al., 2021) . In addition to this existing body of evidence, we further showed that SARS-CoV-2-specific CD8 + T cells are detectable up to 12 months from infections, a hint pointing towards long-lasting immunity similar to SARS-CoV. Of course, continuous follow-up is necessary to strengthen the interpretation of even longer maintenance of CD8 + T cell immunity.

However, whether and how CD8 + T cells may mediate protective immunity in SARS-CoV-2 infections needs to be investigated in more detail. Despite encouraging preclinical data showing loss of protection following CD8 + T cell depletion (McMahan et al., 2021) , evidence of the protective role of CD8 + T cells in humans is still scarce. SARS-CoV-2-reactive CD8 + T cells have often been functionally characterized using ex vivo antigen stimulation-based assays (i.e. IFN-γ ELISpot assays, intracellular cytokine staining, and activation-induced marker), but the use of a single peptide (or peptide mix) dose hinders discrimination of high and low functional T cells. T cell functionality is primarily encoded in its TCR. For this reason, as a first step towards a deeper understanding of the quality of CD8 + T cell responses against this new virus, we investigated the functionality of SARS-CoV-2-specific TCR repertoires in individuals who recovered from mild symptomatic disease. First, we learned that in this clinical situation, SARS-CoV-2 epitope-specific CD8 + T cells are very low in frequency in peripheral blood and difficult to detect ex vivo from a limited sample size. However, a short step of peptide-mediated in vitro expansion (Oh et al., 2011) allowed us to robustly detect SARS-CoV-2-specific CD8 + T cells in convalescent individuals, similar to other reports (Nelde et al., 2020; Schulien et al., 2020; Shomuradova et al., 2020) .

By combining this in vitro peptide expansion with single-cell RNA sequencing, we accessed the MHC class I-restricted TCR repertoire specific towards immunodominant, and thereby relevant, SARS-CoV-2 epitopes. Beside validation of SARS-CoV-2 specificity and peptide sensitivity, of particular importance and uniquely from other studies (Francis et al., 2021) was J o u r n a l P r e -p r o o f the experimental validation that TCRs with high sensitivity towards SARS-CoV-2-specific epitopes can mediate cytotoxicity against virus-infected cells. The association between immunogenicity (the ability of eliciting an immune response) and protection (the direct contribution to the resolution of infection by the elicited immune response) is not selfexplanatory. Immunogenic epitopes can be efficiently cross-presented but eventually not expressed in infected target cells (Holtappels et al., 2004; Kienzle et al., 1998) , in particular for in silico predicted epitopes (Willimsky et al., 2021) , thereby inducing T cell responses that are neither relevant nor indicative of the course of the infection. For two epitopes (A1/ORF3a_FTS or A3/ORF1_VTN), we showed that T cells genetically engineered with SARS-CoV-2-specific TCRs were capable of directly killing virus-infected cells in vitro through specific epitope recognition. This evidence gives an additional value to the epitopes under investigation.

Besides immunogenicity and immunodominance, which has been widely corroborated by other studies where the landscape of HLA class I-restricted SARS-CoV-2 epitopes was exhaustively deciphered (Quadeer et al., 2021) , the epitopes we described are indicative of recruitment of highly functional CD8 + T cell responses. Thus, they represent a particularly useful tools for studying the quality of T cell responses in several contexts e.g. after vaccination and severe infections.

The identification of functional and highly effective SARS-CoV-2-specific TCRs also opens up possibilities for therapeutic use based on TCR-engineered T cells in individuals with high risk of developing a severe clinical course. The therapeutic value of adoptive transfer of antigenspecific, TCR-engineered T cells is well recognized (D'ippolito et al., 2020; D'Ippolito et al., 2019) , especially now that precise genetic engineering offers the flexibility of generating increasingly sophisticated but near-to-physiological autologous T cell products . Furthermore, accumulated evidence supports a model where late recruitment of T cells Tan et al., 2021) , presumably due to a delayed activation of type I interferon response (Combes et al., 2021) , contributes to disease progression, thus offering a therapeutic window for the adoptive transfer of potentially curative TCR-engineered T cells.

Recent findings also disproved initial concerns about the potential role of T cells in immunopathology in advanced COVID-19 diseases, rather attributed to the massive amount of lung-infiltrating neutrophils and circulating monocytes (Park and Lee, 2020) .

A limitation of our study is the use of an in vitro expansion step prior T cell analyses, which may bias the relative abundance of clonotypes and may favor outgrowing of some clones at the expense of others. However, this approach of peptide stimulation offered the possibility of exploiting signatures of recent activation to discriminate epitope-specific and functional TCRs (Fischer et al., 2021) . Indeed, we identified signatures of T cell function and recent activation correlating with TCR functionality, which allowed a broad in silico investigation of the functional landscape of entire TCR repertoires, otherwise unfeasible by conventional experimental J o u r n a l P r e -p r o o f validation. Remarkably, we predicted highly functional TCRs for each of the eleven immunodominant SARS-CoV-2 epitopes analyzed, despite a certain degree of functional heterogeneity. Together with the observed polyclonality, our data indicate that functional and diverse CD8 + T cell immunity should normally establish in non-severe SARS-CoV-2 infections.

Polyclonality and high functionality are hallmarks of a protective TCR repertoire (Song et al., 2017) , thus strongly supporting a similar role also in the context of SARS-CoV-2 infections.

Nevertheless, the extension of TCR repertoire analyses to settings of severe infections remains a fundamental next step to assign CD8 + T cell responses a role as correlates of protection.

Overall, our data provide first evidence that SARS-CoV-2-specific CD8 + T cells persists up to 12 months after infection and are composed of a polyclonal and highly functional TCR repertoire capable of mediating direct killing of virus-infected cells. In addition, we provide tools epitopes and TCRsindicative of functional responses, useful for appropriately investigating and potentially diagnosing correlates of protection in severe patients.

In this study, we limited the selection of SARS-CoV-2 epitopes according to the most common HLA class I molecules in the Caucasian population. The study was conducted in Germany and due to the ongoing pandemic, we were restricted to blood samples from local hospitals only.

Thereby, a representation of other races was limited. Continuous epitope discovery for additional HLAs is necessary to broadly apply our findings to other ethnicities. Further, severely diseased patients have not been included in this study, thus precluding conclusive statements on the role of CD8 + T cells in protection. Finally, all our experiments relied on a step of in vitro expansion, which biased the original phenotype and frequency of SARS-CoV-2-specific T cells. In particular when analyzing severely diseased patients, ex vivo TCR repertoire analyses combined with phenotype assessments may provide a unique setting to clarify the quality of cytotoxic CD8 + T cells in severe COVID-19. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dirk H. Busch (dirk.busch@tum.de) .

This study did not generate new unique reagents.

 Single-cell RNA-seq data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are listed in the key resources table. This paper analyzes existing, publicly available data. These accession numbers for the datasets are listed in the key resources table.

 This paper does not report original code.

 Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

For symptomatic SARS-CoV-2 infections, blood sample was collected at the Helios Clinic West Munich, German Heart Center Munich and University Medicine Mannheim from healthcare employees who were diagnosed by PCR test and experienced mild symptoms (cold, cough and mild fever), for which home quarantine was sufficient (female (f)/male (m)/unknown (u), 32/19/2; age ± SD, 40.5 ± 10.6 years). Participants donated 50 ml blood at the end of the required home quarantine and repeatedly in 4, 8, 12 and 24 weeks following recovery from infection. The study cohort of asymptomatic seropositive (f/m/u, 18/10; age ± SD, 38.4 ± 13.5 years) and seronegative donors (f/m/u, 23/14; age ± SD, 38.8 ± 13.6 years) was established at the Klinikum Rechts der Isar (Munich) and included health care employees that were tested for presence of SARS-CoV-2 specific antibodies in April/May 2020. 10 ml blood was collected at two time points between August 2020 and November 2020. Frozen peripheral blood mononuclear cells (PBMCs) from pre-pandemic (unexposed) donors were received from the Institute for Transfusion Medicine Dresden and collected between 2018 and 2019 (f/m/u, 12/10; age ± SD, 42.96 ± 12.9 years) ( Table S3 ). All participants provided informed written consent. Approval for the study design and sample collection was obtained within the framework of study "Establishment and validation of epitope-specific SARS-CoV-2 blood- 

PBMCs were isolated from whole blood by gradient density centrifugation according to manufacturer's instructions (Pancoll human) and frozen in fetal calf serum (FCS) + 10% DMSO for liquid nitrogen storage. For T cell analyses, PBMCs were thawed and rested for 16 h in RPMI 1640 supplemented with 10% FCS, 0.025% l-glutamine, 0.1% HEPES, 0.001% gentamycin and 0.002% streptomycin before stimulation or expansion procedures.

Virus packaging cell line RD114 and A459-ACE2 RFP + cell lines (with and without additional HLA class I molecules) were cultured in DMEM supplemented with 10% FCS. All cells were cultured in a humidified incubator at 37°C, 5% CO2.

Potential CD8 Table   1 ).

For all time points of blood donation, a serum sample was taken and analyzed for anti-SARS-COV-2 IgG using the iFlash Immunoassay analyzer, following the manufacturer´s protocol.

Briefly, the serum samples were incubated with samples treatment solution and SARS-CoV-2 antigen-coated paramagnetic microparticles to form a complex. Unbound material was washed from the solid phase and a second incubation step with Acridinium-labeled anti-human IgG conjugate followed. After washing, the pre-Trigger and Trigger solutions were added to the J o u r n a l P r e -p r o o f reaction mix and the resulting chemiluminescent reaction was measured as relative light units by the iFlash optical system. A cutoff was calculated from SARS-CoV-2 IgG calibrators.

20% of total PBMCs were pulsed with 10 µg/ml peptide pool for 2 h at room temperature under gentle agitation at 1x10 6 cells/ml. Excess of peptides was removed by washing and peptidepulsed cells were co-cultured with the remaining 80% of PBMCs for 10 -12 days in RPMI 1640 supplemented with 5% human serum, 0.025% l-glutamine, 0.1% HEPES, 0.001% gentamycin and 0.002% streptomycin at 1x10 6 cells/ml. 50 IU/ml IL-2 was added every 3 -4 days.

For ex vivo or expanded primary T cells, PBMCs were stimulated with 1 µg/ml peptide pool, 1 µg/ml peptide or 1 µg/ml PepTivator SARS-CoV-2 Protein S pool. For TCR-engineered T cells, K562 antigen presenting cells (retrovirally transduced with HLA-A1 or HLA-A3) were irradiated (80 Gy), loaded with different peptide concentrations (10 −12 , 10 −11 10 −10 , 10 −9 , 10 −8 , 10 −7 , 10 −6 , 10 −5 and 10 −4 M) overnight at 37°C, and co-cultured with engineered T cells in 1:1 effector:target ratio. Incubation with peptides or antigen-presenting cells was done for 4 h at 37°C, in presence of 1 µg/ml GolgiPlug. DMSO served as negative control whereas 25 ng/ml PMA and 1 µg/ml Ionomycin served as positive control. After incubation, cells were stained with EMA solution (1:1000) for live/dead discrimination and subsequently with surface antibodies: CD19-ECD (1:100), CD8-PE (1:200), CD3-BV421 (1:100) and murine TCR βchain-APC/Fire750 (1:100). Cells were fixed using Cytofix/Cytoperm solution followed by staining for intracellular cytokine by IFN-γ-FITC antibody (1:10). Flow cytometric acquisition was performed on the CytoFlex S Cell Analyzer.

Expanded PBMCs (day 13 post-expansion) were freshly re-stimulated with 1 µg/ml peptide for 4 h at 37°C. Peptide-reacting cells were sorted according to cytokine secretion, detected via IFN-γ catch (IFN-γ-FITC), and CD8 staining (CD8-eF450 1:200). Additionally, donor cells were stained with Total Seq-C antibodies (10x Hashtag 1-6, 0,5 mg/ml) prior sample pooling, in order to discriminate individual donors in the sequencing sample. Flow sorting of CD8 + IFN-γ + and CD8 + IFN-γwas conducted on a MoFlo Astrios EQ under biosafety level 3.

Generic PCR amplification of complete HLA-class I coding regions (HLA-A, -B and -C) were performed in a 11 µl polymerase chain reaction (PCR) assay using 5 µl LongAmp Taq 2x Master Mix, 3 µl forward and reverse primer mix (each 1.5 pmol/µl) and 3 µl DNA (about 10-J o u r n a l P r e -p r o o f 50 ng/µl). The homemade amplification primers were located in the 5'-and 3'-untranslated region. On a SimpliAmp Thermocycler, the thermocycler profile used was a denaturation step at 94°C for 7 min, followed by 15 cycles of denaturation at 94°C for 1 min and annealing /elongation at 66°C for 5 min. Finally, 30 cycles of denaturation at 94°C for 10 s, annealing at 65°C for 50 s and elongation at 72°C for 5 min were performed, with a final hold at 20°C. If necessary, amplification control was performed loading 5 µl of the amplification product on an ethidium bromide stained agarose gel and running electrophoresis for 30 min at 180 V / 80mA. Sanger DNA sequencing itself was run on a 3130xl Genetic Analyzer, using 5 µl Reaction Mix (composed of 0.5 µl BigDye®Terminator v3.1 Cycle Sequencing RR-100, 1.9 µl Q-solution and 2.6 µl water), 5 µl 1:20 diluted amplification product and 5 µl of homemade sequencing primer (exon 1-7; 2.5 pmol/µl). Cycle sequencing assays was performed with a 100-fold approach by a Biomek NXP pipetting roboter. Cycle sequencing itself was run in a SimpliAmp Thermocycler (94°C 2 min, 30 cycles 94°C for 10 s, 60°C 2 min, hold at 20°C). Cycle sequencing reactions were purified using Agencourt CleanSeq magnetic beads in a Biomek NXP protocol following the manufacturer's instructions. Sanger DNA sequencing itself passed on a 3130xl Genetic Analyzer. After import of sequence raw data in the uType software, the sequences were analyzed for HLA type creation by aligning to recent IMGT HLA allele database. 

All detailed information for the strategy of scRNA seq data pre-processing can be found in the uploaded notebooks. All analyses have been performed using SCANPY (Wolf et al., 2018) .

Briefly, cells with less than 200 genes as well as genes present in less than three cells were excluded. Cells with more than 20% mitochondrial genes were excluded and cut-offs for the maximum number of counts (experiment 1: 50.000, experiment 2: 40.000) and number of genes (experiment 1: 7.000, experiment 2: 6.000) were selected individually for the two experiments. Counts were normalized per cell, logarithmized and the variance was scaled to unit variance and zero mean. The number of counts, percentage of mitochondrial genes and cell cycle score was regressed out before highly variable genes were identified and filtered.

The data was batch corrected using batch-balanced k nearest neighbors (bbknn) for the individual donors. Donor reallocation was performed using scSplit (Xu et al., 2019) and HLAgenotyper/gene score for Y chromosome genes (https://www.uniprot.org/docs/humchry.txt) for the first experiment, and souporcell (Heaton et al., 2020) in combination with barcoded antibodies for the second experiment. Since HLA prediction from RNA sequencing data is not very accurate, an HLA score was introduced to allocate donors to clusters derived from scSplit demultiplexing. In principle, HLA matching was scored considering all predictions and all original genotypes in order to find the best match between prediction and genotype.

Genes composing the functionality signature were defined as the top genes correlating with EC50 values of the re-expressed TCRs (r squared > 0.5 and slope > 0.1). Genes composing the reactivity signature were defined by ranking genes per group using t-test and selecting the enriched genes of TCRs that showed an EC50 value after re-expression (-log10(p value) > 250). For CD8 activation score, we used the Gene-ontology CD8 activation score GO:0036037.

Clonotype analysis was performed using scirpy (Sturm1 et al., 2020) . Cells belonging to one clonotype were defined to have identical α and β chain CDR3 nucleotide sequences and both pairs of TRA/TRB sequences were considered in case additional chains have been present.

J o u r n a l P r e -p r o o f

DNA constructs for CRISPR/Cas-9-mediated homology-directed repair (HDR) at TRAC locus were designed in silico with the following structure: 5′ homology arm (300-400 base pairs (bp), P2A, TCR-β (including mTRBC with additional cysteine bridge (Cohen et al., 2007) ), T2A, TCR-α (including mTRAC with additional cysteine bridge (Cohen et al., 2007) ), bGHpA tail, 3′ homology arm (300-400 bp). All HDR DNA template sequences were synthesized by Twist and dsDNA templates were generated via PCR.

To generate 40 µM gRNAs, equal amounts of crRNA hTRAC6 (80 µM) or crRNA hTRBC3 (80 µM) were annealed with tracrRNA (80 µM) at 95°C for 5 min and let allowed to cool down to RT. 20 µM electroporation enhancer (400 µM) was added to gRNA. Cas9 (61 µM) was diluted to 6 µM or 20 µM with PBS for electroporation of 1x10 6 cells or > 5x10 6 cells. Final RNPs were generated by addition of equal volumes of Cas9 to gRNA and incubation for 15 min at RT. For electroporation, hTRAC6, hTRBC3 (3 µl for 1x10 6 , 1 µl for > 5x10 6 cells) and HDR template (1 µg/1x10 6 cells) were incubated at RT for at least 30 sec. PBMCs isolated from whole blood of healthy donors were then resuspended in P3 buffer, added to CRISPR reagents for nucleofection (EH-100) and cultured in medium with 180 IU/ml IL-2. Antibiotics were supplemented to the media after 24 h post-nucleofection. TCR sequences for reexpression are listed in Supplementary 4.

All pHLA monomers were produced in-house as previously described (Effenberger et al., 2019) . For multimer staining, 0.4 µg biotinylated pMHC was multimerized on 0.1 µg fluorophore-conjugated StrepTavidin backbone in a final volume of 50 µl. Up to 5x10 6 cells were incubated with 50 µl fluorescent-labelled multimers for 45 min on ice protected from light.

Surface antibody staining was added after 25 min and incubated for remaining 20 min. Surface marker for TCR KI and multimer stainings covered mTRBC-PE (1:100), CD8-FITC (1:100), CD3-PC7 (1:100).

A549-ACE2 RFP + cells were kindly provided by the group of Professor Andreas Pichlmair.

These cells have been previously engineered to express the SARS-CoV-2 surface receptor protein ACE2 and red fluorescent protein (RFP). A549-ACE2 RFP + cells were then retrovirally transduced with plasmids encoding HLA-A*01:01 or HLA-A*03:01. Cells were additionally cotransduced with blue fluorescent protein (BFP) for selection of transgene expressing cells. For the production of retroviral particles, RD114 cells were transfected with pMP71 expression vector (containing the HLA heavy chain construct, gag/pol and amphotropic envelope) by calcium phosphate precipitation. For this, 15 µl of a 3.31 M CaCl2 was mixed with 18 µg vector J o u r n a l P r e -p r o o f DNA and filled up to a total of 150 µl with ddH2O. This mix was slowly added under vortexing to 150 µl transfection buffer containing 274 mM NaCl, 9.9 mM KCl, 3.5 mM Na2HPO4 and 41.9 mM HEPES. Subsequently, transfection mix was added to RD114 cells and incubated for 6 h at 37°C, 5% CO2 followed by a complete medium exchange. Virus supernatant was harvested three days later and coated on retronectin-treated well plates via centrifugation at 3000 g, for 1 h at 32°C. Subsequently, 1x10 5 A549-ACE2 RFP + cells were transduced via spinoculation at 2000 g for 30 min at 32°C. Successfully transduced cells were purity sorted three days after for HLA-A*03 expression. In the case of HLA-A*01, cells were sorted for BFP expression.

Production and quantification of GFP-expressing SARS-CoV-2 stocks have been performed as previously described (Stukalov et al., 2021; Thi Nhu Thao et al., 2020) . For the Incucyte killing assay, 5x10 3 A549-ACE2 + RFP + HLA-A*01 or A549-ACE2 + RFP + HLA-A*03 cells were 

Data was displayed using GraphPad Prism (V9.1) or the seaborn (0.10.0) and matplotlib (3.1.3) packages in python. Statistical and correlation analyses were performed in GraphPad Prism and with stat.linregress method from the scipy (1.4.1) module, respectively. Significance is defined as *p-value < 0.05, **p-value < 0.01,***p-value < 0.001, ****p-value < 0.0001.

Information on statistical tests used for individual figures can be found in the figure legends.

Supplementary Table 1. List of selected SARS-CoV-2 derived 9-mer epitopes (related to 

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Low avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

CD8+ T Cells Orchestrate pDC-XCR1+

Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming

T cell affinity maturation by selective expansion during infection

Large clonal expansions of CD8+ T cells in acute infectious mononucleosis

Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond

Global absence and targeting of protective immune states in severe COVID-19

Needle in a haystack: The naïve repertoire as a source of T cell receptors for adoptive therapy with engineered T cells

T cell engineering for adoptive T cell therapy: safety and receptor avidity

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

FLEXamers: A Double Tag for Universal Generation of Versatile Peptide-MHC Multimers

Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping

Virus-specific CD8+ T cells in primary and secondary influenza pneumonia

Allelic variation in Class I HLA determines preexisting memory responses to SARS-CoV-2 that shape the CD8+ T cell repertoire upon viral exposure

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells

Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Souporcell: robust clustering of single-cell RNA-seq data by genotype without reference genotypes

Dynamics of Human Respiratory Virus-Specific CD8 + T Cell Responses in Blood and Airways during Episodes of Common Cold

Cytomegalovirus Misleads Its Host by Priming of CD8 T Cells Specific for an Epitope Not Presented in Infected Tissues

Protective immunity towards intracellular pathogens

RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells

Identification of a Cytotoxic T-Lymphocyte Response to the Novel BARF0 Protein of Epstein-Barr Virus: a Critical Role for Antigen Expression

In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific

Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Correlates of protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity

Identification of resident memory CD8 + T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue

Engineering T Cells Specific for a Dominant Severe Acute Respiratory Syndrome Coronavirus CD8 T Cell Epitope

Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19

Human class-I restricted T cell associated molecule is highly expressed in the cerebellum and is a marker for activated NKT and CD8+ T lymphocytes

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform

CRTAM is negatively regulated by ZEB1 in T cells

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Orthotopic replacement of T-cell receptor α-and β-chains with preservation of near-physiological T-cell function

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV

Scirpy: A Scanpy extension for analyzing single-cell T-cell receptor-sequencing data

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection

In vitro proteasome processing of neosplicetopes does not predict their presentation in vivo

SCANPY: large-scale single-cell gene expression data analysis

Genotype-free demultiplexing of pooled single-cell RNA-seq

Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus

Regulation of a Late Phase of T Cell Polarity and Effector Functions by Crtam

Complete but curtailed T-cell response to very low-affinity antigen

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

We thank Max Koch for the processing of blood for PBMCs isolation. We gratefully acknowledge Catharina Gerhards, Margot Thiaucourt and Laura Mirbach for their contribution in the logistic organization of blood sample delivery.This study was supported by the EIT Health CoViproteHCt #20877, the German National Network of University Medicine of the Federal Ministry of Education and Research (BMBF;

reactivity TCR clonotype found in 2 cells TCR clonotype found in 1 cell J o u r n a l P r e -p r o o f Highlights  SARS-CoV-2-specific CD8 + T cells are detectable up to12 months post infection  scRNA sequencing reveals polyclonal CD8 + T cells with variable functionalities  high avidity CD8 + T cells engineered with SARS-CoV-2 specific TCRs are cytotoxic  single cell signature for highly functional SARS-CoV-2-specific CD8 + T cells eTOC Blurb Wagner et al. detect CD8 + T cell responses to diverse immunodominant SARS-CoV-2 specific epitopes. ScRNA-sequencing of epitope responsive CD8 + T cells reveal a polyclonal T cell receptor repertoire. State of the art TCR re-expression confirm a highly specific and functional T cell response in convalescent mild COVID-19.